Navigation Links
Experimental targeted therapy shows early promise against medulloblastomas
Date:6/7/2010

(CHICAGO June 5, 2010) Researchers from St. Jude Children's Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas.

The study is the first to report that the drug can be safely administered to children. The study also suggested that the drug is showing early signs of efficacy in this patient population, with some children still on treatment almost a year with no progression of disease. All the children on this study had medulloblastomas that persisted or returned despite standard treatment with radiation and chemotherapy. Recurrent medulloblastoma currently has a cure rate of less than 5 percent.

The researchers found that patients whose tumors had the Hedgehog molecular pathway activated appear to be some of the same patients who have responded to treatment in this trial, based on length of time on study. Investigators have observed tumor responses in similar young adult patients whose tumors had the Hedgehog molecular pathway activated. These early findings have given the green light for pediatric research to advance to a larger Phase II study scheduled to open later this year, and to increase the number of patients on the young adult study.

The Phase I study (PBTC -025) included 13 patients, 12 of them evaluable, ranging in age from 4 to 21 years. All received one of two different doses of GDC-0449 daily for a minimum of 28 days and continued on treatment for as long as their disease remained stable. In addition to determining the safety and dosing of this experimental drug for children, the trial also conducted extensive research into pathologic and genomic methods for better ident
'/>"/>

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-297-9875
St. Jude Children's Research Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Experimental Vaccine Shields Monkeys Against Ebola
2. Experimental Drug Offers Hope for Cystic Fibrosis Patients
3. Experimental stem cell treatment arrests acute lung injury in mice, study shows
4. Targeted Therapy Shows Promise Against Deadly Brain Cancer
5. Targeted Radiation for Early Breast Cancer a Good Option: Study
6. Blocking DNA repair protein could lead to targeted, safer cancer therapy
7. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
8. Women Smokers Targeted on World No Tobacco Day
9. Drug in new class of targeted therapies shows early promise against blood-related cancers
10. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
11. Gene-Targeted Therapy Might Help Prevent Paralysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (PRWEB) October 31, 2014 Springboard ... for its small scale BioPro™ biodiesel processors, announced ... will further improve the performance and efficiency of ... GL95/MC12/BD380 trio will recover more than ... in with the glycerin by-product produced while making ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org reveals that ... suffered from Alzheimer's disease. , In fact, Alexander Lynch ... disease. His father pointed a gun and shot him during ... author of this method understood that he needed to do ... program is based on years of research. The author of ...
(Date:10/31/2014)... 2014 At the start of 2014, ... escaping carbon monoxide poisoning in their homes. Now, as ... one family-owned, Missouri-based heating and cooling company is taking ... families start the home heating season with the assurance ... , Beginning Nov. 1, 2014, E and Q Heating ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Surgery for low ... where in the United States you live, a new ... experience low back pain at some point in their ... professional medical care for a spine problem," co-author Brook ... Clinical Practice, said in a college news release. ...
(Date:10/31/2014)... insomnia is a major contributor to deaths caused by ... results underscore the importance of the "Sleep Well, Be ... , Results show that the risk of unintentional fatal ... of insomnia symptoms present. People with all three symptoms ... from a fatal injury than those with no insomnia ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... Congratulate Players, MCKINNEY, Texas, Nov. 10 ... cards last night following the,Nationwide Tour Championship at ... PGA TOUR,s newest official marketing,partner, hosted a celebratory ... for their achievement., "This class adds to ...
... to spur cancer,s growth could actually hinder rather than ... the University of California, San Diego. , The findings ... strangling its blood supply have been disappointing when used ... combined with traditional chemotherapy. , Despite their rapid progression, ...
... Cancer cells are already stressed by the fast pace they require ... just may kill them. , "Think about an assembly line in ... Dr. Kapil Bhalla, director of the Medical College of Georgia ... workers to keep going. Some of them fall out, some get ...
... Pennsylvania Facilities Meet Federal Standards, HARRISBURG, Pa., ... reports today showing that all of the 76,mammography ... this year,are operating within the guidelines set forth ... inspects each of Pennsylvania,s approximately 400 certified,mammography facilities ...
... to present results from Phase 1/2 Clinical Trial of,Perifosine ... 2008 at 8:30am, NEW YORK, Nov. 10 ... data from its Phase 1/2 clinical,trial of KRX-0401 (perifosine) ... Annual Meeting of the American Society of Hematology,(ASH), to ...
... NEW YORK, Nov. 10 The American Society ... (RPR) to educate the public on the interventional ... use to,relieve pain., Founded in 1998, ASIPP ... all interventional pain physicians. ASIPP members are board,certified ...
Cached Medicine News:Health News:Top 25 Nationwide Tour Players Earn PGA TOUR Cards for 2009 Season 2Health News:Top 25 Nationwide Tour Players Earn PGA TOUR Cards for 2009 Season 3Health News:Tumors grow faster without blood-supply promoting molecule 2Health News:Researchers aim to over-stress already taxed mantle cell lymphoma cells 2Health News:Researchers aim to over-stress already taxed mantle cell lymphoma cells 3Health News:DEP Releases Third Quarter Mammography Inspections 2Health News:DEP Releases Third Quarter Mammography Inspections 3Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 2Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 3Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 4Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 5Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 6Health News:Rubenstein Public Relations to Launch National Campaign for The American Society of Interventional Pain Physicians 2
(Date:10/31/2014)...  Digirad Corporation (Nasdaq: DRAD) today announced that it has ... PDII ), a healthcare commercialization services company, responding to ... company.  Digirad calls upon PDI to ... to operate in the ordinary course of business and ... debt, on acquisitions or other extraordinary transactions. Digirad believes ...
(Date:10/31/2014)... Oct. 31, 2014 Mast Therapeutics, Inc. (NYSE ... results for the quarter ended September 30, 2014. ... Officer, said:  "The third quarter was productive for Mast. Consistent ... of MST-188 for sickle cell disease is on track ... now have opened 50 study sites in the U.S. ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... economy recovery continues to lag, employers are looking for ... costs. Running counter to these goals, independent drugstores are ... to save money by offering lower cost home delivery ... (PCMA) said today. "As the economic recovery ...
... VIRGINIA BEACH, Va., July 8, 2011 The Amerigroup ... check to the Rx Partnership to benefit the Rockbridge ... is an organization that works to provide uninsured Virginians ... as a broker to access and distribute free bulk ...
Cached Medicine Technology:As Economic Recovery Sputters, Independent Drugstores Shouldn't Shoulder Employers With Higher Costs 2Amerigroup Foundation Presents Grant to Rx Partnership 2
For use with E0828 needle and gouge set and E0828 C handle. Straight gouge shape tip. Polished finish. Most popular size or model....
Set consists of one each:E0824 A replacement burr set. E0824 B handle....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Long 32 mm. Overall length: 3.9 inches. Most popular size or model....
Medicine Products: